USPTO Examiner XU QING - Art Unit 1656

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18438285CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOFFebruary 2024April 2025Allow1410YesNo
18417919METHODS, DEVICES, AND KITS FOR PURIFYING AND LYSING BIOLOGICAL PARTICLESJanuary 2024April 2025Abandon1511NoNo
18398650FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIADecember 2023April 2025Allow1621YesNo
18484844TRIPLE SYRINGE AND METHODS OF MAKING PLATELET-ENRICHED PLASMA AND USE THEREOFOctober 2023September 2024Allow1210YesNo
18467616SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELDSeptember 2023April 2025Abandon1911YesNo
18222788MARINE ALGAE FOR INSECT BIOCONTROLJuly 2023June 2025Abandon2340NoNo
18222798MARINE ALGAE FOR INSECT BIOCONTROLJuly 2023May 2025Abandon2240NoNo
18124877MARINE ALGAE FOR INSECT BIOCONTROLMarch 2023February 2024Allow1121YesNo
18104500Use of Oxyhydrogen Microorganisms for Non-Photosynthetic Carbon Capture and Conversion of Inorganic and/or C1 Carbon Sources into Useful Organic CompoundsFebruary 2023January 2025Allow2331YesNo
17795483MICROBIAL LIPID PRODUCTION UTILIZING POST-FERMENTATION INDUSTRIAL WASTE STREAM FEEDSTOCKSJuly 2022June 2025Abandon3501NoNo
17730891BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISORDERSApril 2022December 2023Allow2020NoNo
17658635METHOD FOR PROMOTING HAIR GROWTHApril 2022April 2024Allow2420NoNo
17592167Use of Oxyhydrogen Microorganisms for Non-Photosynthetic Carbon Capture and Conversion of Inorganic and/or C1 Carbon Sources into Useful Organic CompoundsFebruary 2022September 2024Abandon3211NoNo
17573162METHODS FOR ALLEVIATING ENTERIC PATHOGENIC BACTERIUM-ASSOCIATED DISORDER AND INHIBITING GROWTH OF ENTERIC PATHOGENIC BACTERIAJanuary 2022July 2024Abandon3020NoNo
17552187LACTOBACILLUS REUTERI GMNL-263 FOR IMPROVING HYPERTENSION AND ITS COMPOSITIONS THEREOFDecember 2021March 2025Allow3920YesNo
17520587NOVEL SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELDNovember 2021June 2023Allow2031YesNo
17515297ENERGY DRINKS AND OTHER NUTRITIONAL AIDS DERIVED FROM AGAVE-BASED SPIRITSOctober 2021August 2024Allow3311YesNo
17512813Anti-aging Composition Containing Akkermansia Muciniphila as Active Ingredient and a Method for Preventing Aging Using ThereofOctober 2021November 2024Abandon3750NoNo
17503196SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELDOctober 2021February 2025Abandon4010NoNo
17230665COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF RECURRENT CYSTITISApril 2021November 2023Allow3110YesNo
17225409Methods and Systems for Measuring Plasma Renin ActivityApril 2021February 2025Abandon4601NoNo
17223277TRIPLE SYRINGE AND METHODS OF MAKING PLATELET-ENRICHED PLASMA AND USE THEREOFApril 2021July 2023Allow2700NoNo
17157356PLANT AND PROCESS FOR THE PRODUCTION OF DESULFURIZED BIOGASJanuary 2021September 2023Abandon3201NoNo
17156998ISOPROPYLMALATE SYNTHASE VARIANT AND A METHOD OF PRODUCING L-LEUCINE USING THE SAMEJanuary 2021November 2023Allow3420NoNo
17253587LAS-DEGRADING AND/OR N-REMOVING BACTERIUM AND APPLICATION THEREOFDecember 2020September 2024Abandon4521YesNo
17251486PHARMACEUTICAL COMPOSITION FOR TREATING SEVERE COMPLEX IMMUNODEFICIENCY COMPRISING FUSION PROTEIN OF CELL PENETRATING PEPTIDE AND ADENOSINE DEAMINASEDecember 2020December 2024Abandon4810NoNo
17079942FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIAOctober 2020September 2023Allow3511YesNo
17048443ADDITIVES FOR PROTEIN FORMULATIONS TO IMPROVE THERMAL STABILITYOctober 2020October 2024Abandon4811NoNo
17066163SOMATIC STEM CELLS FOR TREATING BONE DEFECTSOctober 2020August 2023Abandon3401NoNo
16977466RESISTANCE INDUCING AGENT FOR PLANTSSeptember 2020February 2023Allow2921NoNo
16971946BIO-STIMULANT FORMULATIONAugust 2020November 2024Abandon5131NoNo
16984721Cosmetic Compositions And Methods for Improving Skin ConditionsAugust 2020August 2023Allow3621NoNo
16895485CELL CULTURE CONTAINERJune 2020December 2023Abandon4201NoNo
16886254Synthesis Of Enzyme-Polymer Conjugates, Having Enhanced Activity & StabilityMay 2020July 2023Abandon3721YesNo
16761037PRODUCTS OF MANUFACTURE AND METHODS TO ENRICH FOR AND ISOLATE VIRUSES OR PHAGES CAPABLE OF TARGETING SPECIFIC MICROBESMay 2020July 2024Allow5121YesNo
16864048DROPLET-BASED MONITORING OF BIOLOGICAL SAMPLESApril 2020August 2024Abandon5131NoNo
16645281VECTORS, GENETICALLY MODIFIED BACTERIA, AND METHODS OF MAKING AND USINGMarch 2020December 2023Allow4541YesNo
16807895PRESERVED TISSUE PRODUCTS AND RELATED METHODSMarch 2020March 2024Allow4911YesNo
16634898CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOFJanuary 2020November 2023Allow4511NoNo
16689978BIOREMEDIATION USING CO-METABOLISM SUBSTRATESNovember 2019August 2023Allow4431YesNo
16680552METHOD FOR DIAGNOSING CANCER, ASSESSING CANCER PROGNOSIS, MONITORING CANCER, OR ASSESSING EFFECTIVENESS OF CANCER TREATMENTNovember 2019September 2023Abandon4611NoNo
16657304BIOLOGICAL ORE PROCESSING FOR THE ISOLATION OF HEAVY METALSOctober 2019March 2023Allow4120YesNo
16580516Non-Pressurised Pre-Treatment, Enzymatic Hydrolysis And Fermentation Of Waste FractionsSeptember 2019April 2025Abandon6060YesNo
16491408PREPARING AND USE OF GLU-PLASMINOGEN FROM BLOOD FRACTIONSSeptember 2019April 2023Allow4421YesNo
16518544SENSOR FOR NADP (H) AND DEVELOPMENT OF ALCOHOL DEHYDROGENASESJuly 2019August 2023Allow4930YesNo
16515659MINERAL SUPPLEMENTATION IN ALGAEJuly 2019June 2023Abandon4711NoNo
16469043METHODS FOR ASSESSING TREATMENT WITH A GASTROINTESTINAL IMPLANTJune 2019March 2024Allow5721YesNo
16401906PROCESS FOR DETERMINING ENZYME ACTIVITY IN A CELL BY ACTIVITY-BASED REPORTER GENE TECHNOLOGY (ABRGT)May 2019September 2023Allow5231YesNo
16378729IDENTIFICATION OF ANTICOAGULANTS IN A SAMPLEApril 2019July 2023Allow5241YesNo
163797303D Cell Viability AssayApril 2019April 2024Allow6031YesNo
16375310OPTICAL DETECTION OF BIOLOGICAL COMPONENTSApril 2019May 2024Abandon6021NoNo
16333795BIOMASS MONITORING PROCESS AND BIOMASS MONITORING PROBE SUITABLE TO PERFORM THE PROCESSMarch 2019May 2024Abandon6021NoNo
16296172BIO-ASSISTED PROCESS FOR CONVERSION OF CARBON DIOXIDE TO FUEL PRECURSORSMarch 2019February 2024Allow6021YesNo
16329910FATTY ACID ESTERS AGAINST INFECTIONS IN FERMENTATIONSMarch 2019March 2024Allow6061YesNo
16326032BIOLOGICAL ANTIFUGAL LIQUID PREPARATION WITH MICROORGANISM PYTHIUM OLIGANDRUM AND METHOD OF PRODUCTIONFebruary 2019February 2025Abandon6031YesNo
16185387SANGHUANGPORUS SANGHUANG STRAINS AND THEIR PRODUCTS, EXTRACTS AND APPLICATIONSNovember 2018March 2024Abandon6031YesNo
16096465IN VITRO SYSTEM FOR EVALUATING THE EFFECTIVENESS OF A DEODORANTOctober 2018September 2023Allow5921YesNo
16076424MIXTURES AND COMPOSITIONS COMPRISING PAENIBACILLUS STRAINS OR FUSARICIDINS AND CHEMICAL PESTICIDESAugust 2018July 2024Allow6041YesNo
16051747Methods of Populating a Gastrointestinal TractAugust 2018February 2024Abandon6061YesNo
16036645Methods and Systems for the Use of Photosynthetic Microbes as Mechanical Transducers and SensorsJuly 2018January 2024Allow6021YesNo
15742737LIGHT-DRIVEN SYSTEM AND METHODS FOR CHEMICAL MODIFICATION OF AN ORGANIC SUBSTRATEJanuary 2018January 2023Allow6041YesNo
15125260SYSTEM FOR ATTRACTING FLYING INSECTS AND ARACHNIDSSeptember 2016April 2023Abandon6051NoYes
14916961USE OF A COMPOSITION COMPRISING MICROORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTYRIC ACID, FOLIC ACID OR NIACIN AND/OR DECREASE THE INTESTINAL PRODUCTION OF SUCCINIC ACIDMarch 2016July 2023Allow6081YesYes
14773887MICROBIAL COMPOSITIONS COMPRISING RUMEN MICROFLORA AND USES THEREOFSeptember 2015December 2023Allow6071YesNo
14118674METHOD FOR EXTRACTING SQUALENE FROM MICROALGAENovember 2013August 2017Allow45120YesYes
13992113METHOD OF UTILIZING REFUSES IN URBAN AND RURALJune 2013July 2017Allow4941YesNo
13869650DETECTION OF MICROORGANISMS INVOLVED IN METABOLISM OF ORGANIC ENVIRONMENTAL POLLUTANTSApril 2013November 2014Allow1811YesNo
13573627Topical skin care formulationsSeptember 2012April 2013Allow710NoNo
13341010MULTIFUNCTIONAL BIOMATERIALS AS SCAFFOLDS FOR ELECTRONIC, OPTICAL, MAGNETIC, SEMICONDUCTING, AND BIOTECHNOLOGICAL APPLICATIONSDecember 2011June 2014Allow2930YesNo
11916112METHOD FOR SELECTING STABLE PROTEINS IN NON-STANDARD PHYSICOCHEMICAL CONDITIONSNovember 2007October 2017Allow6061YesNo
11823334Modified ribonucleasesJune 2007April 2014Allow6031YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XU, QING.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
4
(100.0%)
Filing Benefit Percentile
0.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner XU, QING - Prosecution Strategy Guide

Executive Summary

Examiner XU, QING works in Art Unit 1656 and has examined 69 patent applications in our dataset. With an allowance rate of 60.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner XU, QING's allowance rate of 60.9% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by XU, QING receive 2.61 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by XU, QING is 45 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +54.4% benefit to allowance rate for applications examined by XU, QING. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.0% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 32.4% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.8% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.